Shakeup at China FDA after chief vaults to the helm of a regulatory umbrella group, new agency head named
Four days ago, China’s Congress passed a massive government overhaul that consolidates the duties of China’s FDA under the umbrella of a market supervision administration and spits out a separate drug regulator. Today, news came out that former CFDA chief Bi Jingquan will head that umbrella agency while one of his deputies, Jiao Hong, will take up the newly created China Drug Administration.
First appointed to the CFDA in 2015, Bi has been the face of reform at the drug regulator, vowing to speed up domestic innovation and encourage foreign investment while remaining strict on drug safety. Clearing up the backlog of clinical trial and marketing applications, accepting data from overseas trial sites and sanctioning contract manufacturing agreements are among the most well-known policy changes during his tenure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.